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Abstract
Background: Cutaneous melanoma is one of the most serious skin cancers. It is caused by neural crest-derived
melanocytes - pigmented cells normally present in the epidermis and, sometimes, in the dermis.
Methods: We performed a review of current knowledge on the risk factors of cutaneous melanoma. Relevant
studies were identified using the PubMed, Science Direct, Medline, Scopus, Scholar Google and ISI Web of
Knowledge databases.
Results: Melanoma incurs a considerable public health burden owing to the worldwide dramatic rise in incidence
since the mid-1960s. Ultraviolet radiation exposure is the predominant environmental risk factor. The role of
geographical (latitude) and individual factors such as skin type, life style, vitamin D levels and antioxidant
protection, sunburn, and exposure to other environmental factors possibly contributing to melanoma risk (such as
cosmetics including sunscreen, photosensitising drugs, and exogenous hormones) are reviewed in this article.
Recently, both rare high risk susceptibility genes and common polymorphic genes contributing to melanoma risk
have been identified.
Conclusions: Cutaneous melanoma is a complex cancer with heterogeneous aetiology that continues to increase
in incidence. Introduction of new biomarkers may help to elucidate the mechanism of pathogenesis and individual
susceptibility to the disease, and make both prevention and treatment more effective.
Background
Cutaneous melanoma is one of the most serious skin
cancers. It is caused by neural crest-derived melanocytes -
pigmented cells normally presented norma in the epider-
mis and, sometimes, in the dermis [1]. Incidence of
melanoma is increasing. While in US the lifetime risk of
melanoma in 1935 was one in 1 500 persons, in 1960 it
was one in 600 persons, and in 2000 it was one in 75 per-
sons [2]. The progression of the melanocyte to a malignant
melanoma involves various sequential steps: development
of benign naevocellular naevus preneoplastic dysplastic
naevus primary melanoma and metastatic melanoma [3].
There are four main types of cutaneous malignant mela-
noma [4,5]: a) Superficial spreading malignant melanoma
which is the most common among Caucasians and
accounts for 70 percent of all melanomas. It usually occurs
in adults and may develop anywhere on the body but
appears with increased frequency on the upper back of
both men and women and on the legs of women; b) Nod-
ular melanoma (accounting for 15 to 30 percent of all mel-
anomas), a dome-shaped, pedunculated or nodular lesion
that may occur anywhere on the body. It is commonly
dark brown or reddish brown but may occasionally be
amelanotic. Nodular melanomas tend to rapidly invade
the dermis from the onset with no apparent horizontal
growth phase. These tumors are frequently misdiagnosed,
because they may resemble blood blisters, hemangiomas,
dermal nevi or polypi; c) Lentigo maligna melanoma
(which accounts for 4 to 10 percent of all melanomas) ori-
ginates from lentigo maligna. Untreated lentigo maligna
tends to exhibit horizontal or radial growth with epidermal
involvement for many years (often decades) before it
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become lentigo maligna melanoma. This change is often
indicated clinically by the development of focal papular or
nodular areas; d) Acral lentiginous melanoma (2 to 8 per-
cent of all melanomas) occurs on the palmar and plantar
surfaces, the digits and the subungual areas.
Although the prognosis of thin melanoma is relatively
good, prognosis decreases with increased thickness of the
lesions. The diminished prognosis is mainly due to the
well established tendency of melanoma to metastasize,
which accounts for 75 percent of all deaths associated
with skin cancer. In addition, melanomas are highly resis-
tant to most forms of chemotherapy and radiation; there-
fore, cure of the disseminated disease is uncommon [6].
In women, melanoma often develops in the extremities,
most commonly the lower limbs. In men, melanoma is
most often found on the trunk, on the area between the
shoulders and hips. In both sexes, melanoma can appear
on the palms or soles and under the fingernails or
toenails [7].
Methods
An extensive literature search was performed to review
current knowledge on cutaneous melanoma including epi-
demiological studies addressing risk factors of cutaneous
melanoma between 1998 and 2010. Relevant studies were
identified using the PubMed, Science Direct, Medline,
Scopus, Scholar Google and ISI Web of Knowledge
databases.
Results – Melanoma risk factors
Sunlight exposure
Sun exposure plays a primary and supporting role in
most melanoma tumors. There is evidence that for the
four main cutaneous types of melanomas, the pattern of
excess sunlight exposure which is most damaging varies
[8,9,5]. The environmental human carcinogen present in
sunlight is ultraviolet (UV) irradiation [10]. The sun
emits UVA (l=320-400 nm), UVB (l=280-320 nm), and
UVC (l=200-280 nm) ultraviolet radiation. While UVC
radiation is ecologically not relevant since it is absorbed
by oxygen and ozone in the Earth’s atmosphere, the
longer wavelength UV-B (280–315 nm) and UV-A (315–
400 nm) radiation have significant effects on the biota.
98.7% of the ultraviolet radiation that reaches the Earth’s
surface is UVA [11,12]. The molecular mechanisms by
which UV radiation exerts its varied effects are not fully
understood; however, it is thought that UV irradiation
plays a critical role in melanoma formation [1]. Cur-
rently, it is thought that the DNA damaging, carcino-
genic, inflammatory, and immunosuppressive properties
of UVR all contribute to initiation, progression, and
metastasis of primary melanoma [13]. Reactive oxygen
species (ROS) overproduction may stimulate malignant
transformation to melanoma. Changes in ROS signalling
pathways play also important role in the damaging action
of UVA and UVB irradiation on the skin [14].
Natural photoprotection
The term photoprotection designates the mechanisms that
nature has developed to minimize the damage that the
human body suffers when exposed to UV-irradiation. This
damage mostly occurs on the skin, but other parts of the
body (especially the testicles) can be affected by UV-light.
Photoprotection of the human skin is achieved by the
extremely efficient internal conversion of molecules which
originally absorb the UV-photon - endogenous chromo-
phores: DNA nucleotides, urocanic acid, proteins, amino
acids, melanin and their precursors and metabolites [15].
Internal conversion is a photochemical process that con-
verts the energy of the UV-photon into small amounts of
heat. These small amounts of heat are harmless. The
energy of the UV-photon not transformed into heat leads
to the generation of various harmful reactive chemical spe-
cies (e.g. singlet oxygen or hydroxyl radical) [16,17].
In DNA this photoprotective mechanism evolved four
billion years ago. The purpose of this extremely efficient
photoprotective mechanism is to prevent direct and par-
tially indirect DNA damage. The ultrafast internal conver-
sion of DNA reduces the lifetime of DNA in the excited
state to only a few femtoseconds (10
-15s) – in this way the
excited DNA does not have enough time to react with
other molecules [18,19,17]. The absorption spectrum of
DNA shows strong absorption for UVB-radiation and
much lower absorption for UVA-radiation (Fig. 1).
It is thought that photoprotection of melanin developed
later in the course of evolution. There are two types of
skin melanin: eumelanin, a black-brown pigment which is
insoluble and is found in brown/black hair and brown
eyes, pheomelanin, reddish pigment which is alkali-soluble
and is found in red hair and red feathers [20]. All healthy
individuals have varying degrees of eumelanin in their
skin, while pheomelanin is present only in individuals who
carry the corresponding genetic trait. It is thought that
eumelanin protection against nutrient photolysis and, spe-
cifically, photolysis of folate (owing to the direct connec-
tion between folate and reproductive success), was a prime
selective inducer which resulted in deeply pigmented skins
among people living under high UVB radiation through-
out most of the year. The importance of increased eumela-
nin production to prevent future direct and indirect DNA
damage, individual fitness of protection of sweat glands
and maintenance of thermoregulatory capability is also
thought to have contributed to increased melanization
[21]. Eumelanin dissipates more than 99.9% of the
absorbed UV radiation as heat. This means that less than
0.1% of the excited melanin molecules will undergo harm-
ful chemical reactions or produce free radicals [22].
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The predominant component of sunlight, UVA, pene-
trates fivefold deeper into skin than UVB due to its
longer wavelengths [23,24]. Whereas UVA can indirectly
damage DNA through the formation of reactive oxygen
radicals, UVB can directly damage DNA causing apopto-
sis of keratinocytes by forming sunburn cells [25]. It has
been shown that 92% of all melanoma are caused by
indirect DNA damage and that only 8% of all melanoma
are caused by direct DNA damage [26].
Direct DNA damage and sunburn
Since the action spectrum of sunburn is identical to the
absorption spectrum of DNA, it is generally accepted
that direct DNA damage is the cause of sunburn [27]. It
can occur when DNA directly absorbs UVB photons.
UVB light causes the formation of covalent linkages
between pairs of thymine and cytosine bases in DNA
and forms pyrimidine dimers (cyclobutane dimer). The
radiation excites DNA molecules in skin cells, causing
aberrant covalent bonds between adjacent cytosine bases
by producing a dimer. During DNA replication, DNA
polymerase incorporates an incorrect base opposite to
an aberrant base, causing a mutation. The mutation
caused by direct DNA damage can lead to skin cancers.
The second most frequent UV photoproducts are 6-4
photoproducts (6-4 PPs), which are pyrimidine adducts
and their Dewar valence isomers formed by the photo
isomerisation of 6-4 PPs by wavelengths longer than
290nm [28-33]. These reactions are quite common: each
cell in the skin might experience 50-100 reactions dur-
ing every second of sunlight exposure. Most of these
genetic lesions are corrected by the mechanism of
nucleotide excision repair. If the damage remains uncor-
rected, the genetic information may be permanently
mutated.
Figure 1 UVR absorption spectra of molecules important to UV-induced health effects DOPA-melanin-synthetic model of eumelanin (J
Longstreth et al, 1998)
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Malignant melanoma is mainly caused by indirect DNA
damage. A limited number of molecules in tissue weakly
absorb UVA irradiation. After UVA irradiation absorp-
tion, these molecules (endogenous photosensitizers)
converts to their long-lived triplet state that allows the
transfer of energy to oxygen molecules. The transferred
energy leads to an energetically excited oxygen molecule
(singlet oxygen), which is highly reactive. Some of the
endogenous photosensitizers have been identified, for
example, flavins [34], NADH/NADPH [35], urocanic
acid [36], and some sterols [37]. 3-hydroxypyridine deri-
vatives comprising a wide range of skin biomolecules,
such as enzymatic collagen cross-links, B6 vitamin, and
likely advanced glycation end products in chronologi-
cally aged skin, constitute a novel class of UVA photo-
sensitizers, capable of skin photooxidative damage [38].
Wenczl et al. [39] demonstrated that UVA-irradiated
cultured human melanocytes are photosensitized also by
chromophores as pheomelanin and/or melanin inter-
mediates. UVB natural chromophores may also exhibit
similar phototoxic properties. Babu and Joshi [40] sug-
gested that UVB-sensitized tryptophan produces singlet
oxygen (
1O2) and superoxide radicals (O2
-.), and these
reactive forms of oxygen may contribute to membrane-,
cytoplasm- and DNA-damaging effects.
Singlet oxygen, hydroxyl radical and hydrogen peroxide
are reactive oxygen species (ROS) considered to be most
responsible for producing oxidative stress in cells and
organisms [41]. Oxidative stress is caused by imbalance
between ROS production and a biological system’s ability
to readily detoxify these reactive intermediates or easily
repair the resulting damage. Thus, oxidative stress is
accepted as a critical pathophysiological mechanism in
cancererogenesis [42]. Reactive chemical species can
reach DNA by diffusion and the bimolecular reaction will
damage the DNA [43]. Singlet oxygen interacts preferen-
tially with guanine to produce 8-oxo-7,8-dihydroguanine
(formed by the loss of two electrons). Further removal of
two electrons from this product can yield spiroiminodi-
hydantoin (Sp) R and S stereoisomers. Both in vitro and
in vivo experiments have shown that the Sp stereoi-
somers are highly mutagenic, causing G –>Ta n dG–>
C conversions. Hence, they are of interest as examples of
endogenous DNA damage that may initiate cancer
[41,44].
Ozone depletion and skin cancer
The radical increase of melanoma that has occurred in
the last years has been associated with ozone depletion
caused by ozone depleting substances (ODS) of anthro-
pogenic origin, resulting in higher UVB radiation reach-
ing the ground. Decreases in ozone have generated
worldwide concern leading to adoption of the Montreal
Protocol banning the production of ODS such as chlor-
ofluorocarbon (CFC), other fully halogenated CFCs
(freons), carbon tetrachloride, hydrochlorofluorocarbons,
hydrobromofluorocarbons, methylchloroform, important
industrial substances like halons (bromofluorocarbon
compounds) and methyl bromide. Ozone depleting sub-
stances were used in automobile and truck air condi-
tioning units, domestic and commercial refrigeration
and air conditioning/heat pump equipment, aerosol pro-
ducts, portable fire extinguishers, insulation boards,
panel and pipe covers and pre-polymers (The Montreal
Protocol on Substances that Deplete the Ozone Layer,
2000). The level of UVB in sunlight is a strong function
of latitude, whereas UVA is not. It is not surprising that
the ratio of non-melanoma skin cancer incidence in
Australia/Norway is an order of magnitude higher than
for cutaneous malignant melanoma [45]. Based on stu-
dies which have found that 92% of all melanoma are
caused by indirect DNA damage from UVA [46], we
assume that other main hazard factors (pigmentary
traits, ethnic origin, benign nevi, or family history) and
not ozone depletion are responsible for radical increase
of melanoma last years.
Sunburn and sunscreens
An increased risk of melanoma was seen with increasing
number of sunburns for all ages, not just childhood.
The magnitude of risk for five sunburns per decade was
shown to be highest for adult and lifetime sunburns
[47].
Although sunscreens prevent sunburn [48-50], epide-
miological or laboratory evidence that they prevent mela-
noma in humans is still missing.
Sunscreens have traditionally been divided into organic
(chemical) absorbers and inorganic (physical) blockers on
the basis of their mechanism of action. The organic com-
pounds absorb high- intensity UV rays with their excita-
tion to a higher energy state. Excess energy is dissipated
by emission at longer wavelengths or relaxation by
photochemical process such as isomerization and heat
release. These organic compounds include para-amino-
benzoic acid (PABA) and PABA esters, salicylates, cinna-
mates, benzophenons, butyl methoxydibenzoylmethane
(Parsol 1789), drometrizole trisulphonic (Mexoryl XL),
terephthalydene dicamphor sulphonic acid (Mexoryl SX),
methylene bisbenzotriazol tetramethylbutylphenol (tina-
sorb M) and anisotriazine (Tinasorb S).
The inorganic agents, which protect the skin by reflect-
ing and scattering UV, are nanoforms of titanium dioxide
(TiO2) and zinc oxide (ZnO). These sunscreens are very
efficient, photostable and offer protection extending into
the UVA and visible range of the electromagnetic spec-
trum with almost negligible irritation. However, these
molecules which reflect/scatter UV can cause whitening
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processed as microfine or nanoparticles (10-50 nm).
Nanoparticles reflect/scatter and absorb UVA and UVB,
and they are transparent on the skin, thus enhancing the
cosmetic acceptability of the product [51].
It was thought that the UV-filter acts as “artificial mel-
anin” but most of sunscreen organic chemicals cannot
dissipate the energy of the excited state as efficiently as
melanin or DNA (Table.1) and, therefore, the penetra-
tion of sunscreen ingredients into the lower layers of
skin increases the amount of ROS [52,53].
Inorganic sunscreen agents (metal oxides) screen
UVA/UVB radiation efficiently, but can also generate
harmful reactive oxygen species and radicals when sub-
jected to UVA/UVB radiation [54,55].
DNA damage can be reduced by topical sunscreen
which stays on the surface of the skin; it is important
that the sunscreen blocks both UVA and UVB [56].
However, if sunscreen penetrates the epidermal barrier
and gets into contact with living tissue, the DNA
damage can be amplified many times, causing damage
to living tissue even at very low concentrations (e.g. 10
μmol/L) [57-59].
Skin penetration of organic UV filters such as ethoxy-
lated ethyl-4-aminobenzoate (PEG-25 PABA), benzophe-
none, benzophenon-3 (oxybenzon), salicylic compounds,
octocrylene, octylmethoxycinnamate has been reported
[52,60,61]. Skin penetration of metal nanoparticles also
causes mistrust of sunscreen products usage [62].
In general, the penetration of rabbit skin > rat > pig >
monkey > human, with the pig skin being about 4 times
or more and the rat skin up to about 9 times more
permeable than human skin for certain compounds [63].
Penetration can also vary depending on the bulk compo-
sition of the compound studied. In most safety testing
experiments pretreated chemicals isolated from sunsc-
reens are used, but incorporated sunscreen chemicals in
cosmetic creams/lotions presented as oil-in-water (O/
W) or water-in-oil (W/O) emulsion enhance the pene-
tration of these pretreated chemicals into the skin
[60,64]. Also the formulation vehicle in which the
sunscreen is presented to the skin has a significant effect
on absorption into the skin [65]. Alcohol-based formula-
tions appear to increase sunscreen absorption. In addi-
tion, some sunscreen chemicals may enhance the skin
absorption of other sunscreens when applied in combi-
nation [66].
Some ingredients in sunscreens protect only against
direct DNA damage, but increase indirect DNA damage
[59,58,67]. It is assumed that this causes an increase in
melanoma cases found repeatedly in sunscreen users
compared to non-users [68-71]. Other studies have
found decreased melanoma risk with increased sunsc-
reen use [72-74]. Discrepancies in reported claims may
be caused by differences in the frequency of use, quanti-
ties used and the sun protection factor (SPF) of sunsc-
reens. Sunscreens used before likely protected only
against UVB, whereas currently sunscreens often have
both UVA and UVB protection. Furthermore, although
most studies include skin phototype and sun sensitivity,
results were not statistically adjusted to account for the
sun sensitivity of study participants (i.e. individuals with
increased risk for sunburn are more likely to develop
melanoma, but they are also most likely to use sunsc-
reens [51].
Photosensitive drugs
Drug-induced photosensitivity may occur in a variety of
ways. Most reactions are generally classified as either
phototoxic or photoallergic. Phototoxic reactions are
chemically-induced reactions when the drug causes a
deeper penetration of UVA light followed by cellular
damage. This reaction can be seen with initial exposure
to a drug and is perhaps dose-related [75,76]. Photosen-
sitization reactions of drugs lead to the formation of
ROS and cause indirect DNA damage [77-80]. It may
occur due to topical or systemic drugs (Table 2) [81].
Cancer risk of cosmetic ingredients
Cosmetic ingredients are absorbed through the skin.
Some chemicals may penetrate the skin in significant
amounts, especially when left on the skin for long
Table 1 Dissipation of photon energy by natural and synthetic organic chromophores
UV-absorber Other names Percentage of molecules that dissipate the
photon energy
DNA > 99.9 %
natural melanin > 99.9 %
2-ethylhexyl 4-(dimethylamino)
benzoate
Padimate-O, octyldimethyl PABA, OD-PABA 10%
4-Methylbenzylidene camphor (4-MBC), (MBC), Parsol 5000, Eusolex 6300 30%
Menthyl anthranilate (MA), Methyl-2-aminobenzoate, meradimate 60%
Ethylhexyl methoxycinnamate (2-EHMC), (EHMC), EMC, Octyl methoxycinnamate, OMC,
Eusolex 2292, Parsol
81%
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from substances in cosmetic and personal care products
have been reported (Table 3) [82].
Components of temporary tattoos and hair dye ingre-
dients, namely para-aminophenol (PAP) and para-phe-
nylenediamine (PPD), have been reported to be
carcinogenic and transformed in human skin [83,84].
However, other studies suggest that consumer or profes-
sional exposure to hair dyes poses no carcinogenic or
other human health risks [85]. Absorption spectra of
these compounds that absorb also UVA /UVB light [86],
and possible penetration of these ingredients from dyes,
can cause UV-induced indirect DNA damage. According
to members of Cosmetic Ingredient Review (CIR), many
cosmetic ingredients are used without sufficient data to
support safety, especially impurities, UV adsorption,
photosensitization, and genotoxicity. Information about
cosmetic ingredients such as benzoxiquine, melamine/
formaldehyde resin, oxyquinoline, oxyquinoline sulfate
etc. should be verified (CIR, 1997, 2006) [87].
Indoor environment
Outdoor workers can get three to nine times as much
solar UVR exposure as indoor workers [88,89]. Para-
doxically, outdoor workers have a lower incidence of
cutaneous malignant melanoma compared to indoor
workers [90-92]. It is supposed that indoor solar UVA
exposure, which causes mutations, depletes vitamin D3
in the skin [93]. In the early 20th century, due to life
style changes, people tended to stay indoors during the
day, which drastically decreased their daily amount of
cutaneous vitamin D3. The UV barrier created by win-
dow glass separated UVB from UVA, so that the vitamin
D making UVB was excluded from our indoor working
environment. It is hypothesized that this unnatural UV
environment, which existed for decades in buildings and
cars, caused cutaneous malignant melanoma incidence
to increase steadily about 20–30 years later in the mid-
1930s. Increased UVA exposure and decreased cuta-
neous Vitamin D3 levels mayb er e s p o n s i b l ef o rt h e
increasing incidence of melanoma [94] (Fig. 2). Mela-
noma cells can convert vitamin D3 to the hormone,
1,25-dihydroxyvitamin D3, or calcitriol, which causes
growth inhibition and apoptotic cell death in vitro and
in vivo [94].
Artificial UV lamps and ionizing radiation
Lamps used for sun tanning emit wavelengths in the
short end of the UVA range. Despite claims from the tan-
ning industry, artificial tanning is not a safe or useful way
to increase systemic vitamin D levels [93,95]. Many stu-
dies indicate a significantly increased risk of cutaneous
melanoma subsequent to sunburn/sunlamp exposure,
especially among individuals who are young, Caucasian,
and female [96-98]. A European study showed that
Table 2 Some drugs associated with photosensitivity
reactions
Frequent Less frequent
Amiodarone Antidepressants (tricylic,
MAOIs)
NSAIDs Antifungals
Phenothiazines (particularly
chlorpromazine)
Antimalarials
Retinoids Benzodiazepines
Sulfonamides Beta-blockers
Tetracyclines (particularly
demeclocycline)
Carbamazepine
Thiazides Griseofulvin
Oral contraceptives
Quinine
Quinolones
Retinoids
St John’s Wort
Sulphonylureas
Table 3 Cosmetic ingredients and cancer risk
Cosmetic substance Risk
DEA (diethanolamine)
TEA (triethanolamine)
can result in formation of carcinogenic nitrosamines
Bronopol (2-bromo-2-nitropropane-
1,3-diol)
may break down into formaldehyde and also cause the formation of nitrosamines
1,2-Dioxane in surfactants/detergents contaminated with carcinogenic 1,4-dioxane
Artificial colours (as Blue 1 and
Green 3)
Carcinogenic
Hair dyes dark colours ingredients are carcinogenic
Cosmetic lanolin can be contaminated with carcinogenic pesticides such as DDT, dieldrin, and lindane, in addition to other
neurotoxic pesticides
Talc Carcinogenic
Silica may be contaminated with carcinogenic crystalline quartz
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for melanoma [99].
More than 40 kinds of skin diseases such as sclerotic
skin disease, vitiligo, atopic dermatitis, localized sclero-
derma etc. can be treated with artificial UVR by three
types of phototherapy, namely, broadband UVB photo-
therapy, narrowband UVB phototherapy, and UVA
phototherapy [100-103]. Phototherapy combined with
chemicals such as oral methoxsalen (psoralen) in combi-
nation with UVA radiation (PUVA) provides a highly
effective therapy for psoriasis and many other skin con-
ditions such as vitiligo [104,105,102,101]. However,
PUVA is carcinogenic and increases melanoma risk.
This risk is greater in patients exposed to high doses of
PUVA. It appears to be increasing with the passage of
time, and should be considered in determining the risks
and benefits of this therapy [106].
It is also suggested that people exposed to ionizing
radiation, e.g., nuclear industry workers, subjects near
nuclear test blasts, survivors of the atomic bombings of
Japan, airline pilots and cabin attendants, recipients of
medical radiation, and radiological technicians may be
at increased risk of developing melanoma [107].
Sex hormones and stimulation of melanocytes
Normal and malignant pigment cells are known targets
for many hormones. Besides alpha-melanocyte-stimulat-
ing hormones and the steroidal hormones estrogen, tes-
tosterone, and glucocorticoids, other factors produced
by epidermal cells can stimulate melanocytes. Among
these factors are the prostaglandins, vitamin D3, ETAF
(epidermal cell-derived thymocyte activating factor), and
interleukin-1 [108]. A relationship between the biologi-
cal behaviour of melanoma and sex hormones action
has been identified in several areas of research. These
observations include different survival prognoses for
females and males, the rarity of melanoma incidence in
prepubescent children, pregnancy and effects of exogen-
ous hormones [109-111]. Estrogen, estradiol and proges-
teron receptors have been observed in human
melanomas [112-114] and, consequently, melanoma
seems to be associated with female hormones.
Sex
The incidence of malignant melanoma is higher among
females than males aged 15-30 years; after age 30, inci-
dence is higher among males [115]. Generally older age
Figure 2 Cutaneous vitamin D3 The cutaneous vitamin D3 “roller coaster” that indoor workers experience during the workweek and workyear
compared to outdoor workers. The curve for indoor workers (solid) rises on some weekends and during most vacations, while for outdoor
workers (dotted) cutaneous vitamin D3 remains fairly constant and above the theoretical line for ‘sufficient’ cutaneous vitamin D3. (Godar D.E.,
2009).
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primary cutaneous melanoma. Females have better prog-
nosis than males but this difference disappears after age
of 65. Younger patients have more favourable prognosis
than older patients; this difference is more pronounced
in women [116].
Pregnancy and melanoma
Melanoma is a major health care problem due to its
growing incidence especially in the younger population.
In some countries 30% to 35% of female melanoma
patients are in their reproductive age [117] and, thus,
melanoma can occur in pregnancy ([118,119]. However,
recent findings from more recent controlled studies sug-
g e s tt h a tt h ed a t ad on o ts u p p o r tam o r ea d v a n c e d
stage, thicker tumors, increased metastases to lymph
nodes, or a worsened survival of pregnant women diag-
nosed with localized cutaneous melanoma [120-124].
Pregnancy generally does not increase the subsequent
risk of having melanoma and there is no increased risk
of melanoma developing during pregnancy [125].
Patients expressing estradiol receptors in melanoma
cells have been reported to have a better prognosis
[114]. There is little evidence that significant changes in
nevi occur during pregnancy [126-128].
Exogenous hormones
Recent multiple studies showed conflicting results on
the association between oral contraceptive use and the
development of cutaneous melanoma. While some stu-
dies suggest a cumulative dose-dependent increased risk
of melanoma with use of estrogens [111], other reports
demonstrate that hormone replacement therapy does
not appear to enhance the risk for developing melanoma
[120]. It is proposed, that estradiol therapy leads to a
decrease of proliferation of melanoma cells and an
increase in melanogenesis [114]. Endogenous estrogenic
metabolite 2-methoxyestradiol was found to have poten-
tial preventive/therapeutic use for melanoma growth
[129].
Skin type and melanocytotic hyperpigmentation
Malignant melanoma mainly afflicts people with white
skin (the Caucasian population). Odd Ratio for influence
by total nevi is 5.37, 95%CI 4.44 to 6.36. Particularly,
dysplastic nevi confer much higher risks than most pig-
ment characteristics [130].
Generally, melanoma and its precursor lesions nevi are
melanocytotic hyperpigmentation caused by proliferation
of active melanocytes. In multiple studies no clear evi-
dence was found to associate melanocytes proliferation
with steroid hormones regulation. On the other hand,
increased melanin production by existing melanocytes
(melanotic hyperpigmentation) is considered to be
stimulated also by hormone regulation via melanocytic
h o r m o n er e c e p t o r s .T h u s ,t h eo c c u r r e n c eo fh o r m o n e
receptors in melanoma cells can be expected because
melanoma cells can express pigment.
Melasma is an acquired hypermelanosis, occurring
symmetrically on sun-exposed areas of the body. The
pigmentation is due to overproduction of melanin by
the pigment cells, melanocytes. Lesions are irregular
light to dark brown macules and patches, usually invol-
ving the forehead, temples, upper lip, and cheeks. Asian
and Hispanic females are most commonly affected
[131-133]. Other authors found possible role of andro-
genic hormones in melasma [134]. Typically, melasma
happens by increased melanin production by existing
melanocytes (melanotic hyperpigmentation) [135]. No
increase in the number of melanocytes in melasma areas
was noted, but these cells are larger, more dendritic and
show increased melanogenesis producing especially
eumelanin [136].
During pregnancy, melanocytic activity increases caus-
ing hyperpigmentation as observed in the linea nigra
(dark line running up the tummy) and the areola and
nipple [137-139]. Occurrence of melasma (also known
as chloasma) is also found to be associated with estro-
gen hormones [140,141]: increased expression of estro-
gen receptors in melasma-affected skin has been
demonstrated [141]. Melasma has been reported in 50-
70% of pregnant women [142-144] and in non pregnant
women who are taking birth control pills [145]. It has
been reported to exist only in 10% of men [146]. Sun
exposure together with other exogenous factors (such as
use of cosmetics and perfumes) are another risk factor
for melasma [147]. It has been also thought to arise
from endocrine disorders, genetic factors, other medica-
tions, nutritional deficiency and hepatic dysfunction
[148].
Family history (germline mutations)
Approximately 5-10% of melanoma occurs in families
with hereditary melanoma predisposition. About 40 % of
familial melanoma is associated with chromosome 9p
[149,150]. Worldwide, approximately 20-40% of kins
with familial melanoma harbour germline mutations in
the CDKN2A gene, located on chromosome 9p21,
which encodes two different proteins, p16INK4 and
p14ARF, both involved in regulation of cell cycle pro-
gression and induction of senescence. There are geogra-
phical variations in the incidence of CDKN2A
mutations. The risk of melanoma in CDKN2A mutation
carriers varies between populations and is higher in
regions with high sun exposure and high incidence of
melanoma in the general population [151]. Another
melanoma susceptibility gene, CDK4, accounts for only
small number of families with germ mutations on
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which normally interacts with p16INK4A [151]. Relative
risk to cutaneous melanoma depends on anatomic dif-
ferences such as body site for skin, or hair colour. These
differences could be attributed to gene variability [152].
DNA polymorphisms/ somatic mutations
A panel of polymorphisms that appears to confer low-
to-moderate risk for melanoma has been assessed
through functional and genome-wide association studies.
Suggested associations between genetic polymorphisms
and melanoma were extensively reviewed [153-157].
Vitamin D receptor (VDR) gene SNPs the FokI T allele
was associated with increased melanoma risk (OR 1.42,
95% confidence interval CI 1.06-1.91). In a meta-analysis
the FokI T allele was associated with increased mela-
noma risk (OR 1.19, 95%, CI 1.05-1.35), and the BsmI A
allele was associated with reduced risk (OR 0.81, 95%,
CI 0.72-0.92). However, other study showed opposite
results: a significant association between the BsmI VDR
polymorphism and increased melanoma risk (OR, 1.30,
95% CI, 1.11-1.53, the population attributable risk
9.2%.). FokI polymorphism did not appear to be asso-
ciated with such risk (OR, 1.09; 95% CI, 0.99-1.21)
[157,158].
Mutations in the cell cycle gene CDKN2A (gene or
mono-allelic loss at the locus) were connected with high
risk of melanoma but results are not clear [159,160].
The oncogenic mutations in the B-RAF and N-RAS
genes constitute the initiating somatic events followed
by loss of a major check point gene mainly CDKN2A or
in some cases p53 or PTEN [159-161].
The DNA repair process is important in protecting
humans from cancer. Multiple DNA repair pathways are
able to repair all kinds of DNA damage induced by exo-
genous and endogenous genotoxic agents, usually in an
error-free manner. Recent reviews show links between
the DNA repair pathways and cancer, particularly the
association between nucleotide excision repair and mela-
noma development (154, 155, 156). Nucleotide excision
repair gene xeroderma pigmentosum variant (XPV)
[154], the c.1783G, p.595V alleles were associated with
melanoma (OR 1.86 CI 1.27-2.71, and OR 1.84 1.29-2.63
respectively). XPD/ERCC2 SNP rs1318, variant C allele
was associated with slightly increased melanoma risk
(OR = 1.12, 95% CI 1.03-1.21, population attributable
risk = 9.6%) [156].
Some of the genetic variants in the DNA repair gene
XRCC1 have also been associated with melanoma.
Patients with variant genotype had better overall survi-
val. MC1R variants were associated with susceptibility to
basal cell carcinoma of skin and there is an interaction
with host factors and the XRCC3 gene [162]. ASIP and
TYR pigmentation variants are also associated with
cutaneous melanoma and basal cell carcinoma. These
results suggest that both nucleotide as well as base exci-
sion repair deficiency may contribute to the develop-
ment of cutaneous melanoma. However, recent results
show that the repair of major DNA damage caused by
cancer drugs is efficient in metastatic melanoma [156].
This implies that in addition to genome association stu-
dies, more research on DNA repair and cell cycle regu-
lation is needed.
Conclusions
Cutaneous melanoma is a complex, heterogeneous can-
cer that is increasing in incidence. Multiple studies have
identified major host and environmental risk factors for
melanoma. The predominant environmental risk factor
is exposure to UV radiation. Geographical and indivi-
dual factors such as sex, skin type (particularly dysplas-
tic nevi) and life style – outdoor/indoor life, sunburn,
vitamin D and antioxidant protections are considered to
be risk factors. Additionally, exposure to other environ-
mental factors such as sunscreen, photosensitising
drugs, and exogenous hormones may also increase the
risk of melanoma. Recently, the association between rare
high risk susceptibility genes and common polymorphic
genes and development of melanoma risk have been
identified. However, more epidemiological as well as
mechanistic studies are needed to understand the causal
mechanisms of melanoma development.
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